Skip to main content

Articles

Original Research, Practice Management, Multiple Sclerosis
Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018
Zizi Elsisi, BPharm; Ana L. Hincapie, PhD; Jeff Jianfei Guo, BPharm, PhD
Stakeholder Perspective
Utilization Challenges of Drugs for Multiple Sclerosis in a Medicaid Population
James T. Kenney, RPh, MBA
Read More
Original Research, Cardiometabolic Health, Mental Health
Mental Health Conditions and Hospitalizations for Ambulatory Care Sensitive Conditions Among Veterans with Diabetes
Drew A. Helmer, MD, MS; Nilanjana Dwibedi, BPharm, MBA, PhD; Mazhgan Rowneki, MPH; Chin-Lin Tseng, DrPH; Dennis Fried, PhD; Danielle Rose, PhD; Nisha Jani, MPH, PhD; Usha Sambamoorthi, PhD
Stakeholder Perspective
Mental Health Conditions Constitute Significant Comorbidity: The Impact on Potentially Avoidable Hospital Admissions
Gary M. Owens, MD
Read More
Letters to the Editor
Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis
Read More
FDA Approvals, Lung Cancer, Oncology
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Read More
FDA Approvals
Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping
Read More
FDA Approvals
Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations
Read More
FDA Approvals
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Read More
FDA Approvals
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Read More
FDA Approvals
FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma
Read More
FDA Approvals, Urothelial Cancer, Oncology
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Read More
Page 37 of 244
Results 361 - 370 of 2436